BioMarin posts $320M pre-tax Alesta acquisition charge for 2026

BioMarin completed the Alesta Therapeutics acquisition on August 31, 2026, and disclosed $283 million in in-process R&D (IPR&D) expense for Q3 2026 and $320 million total pre-tax charges for full-year 2026, representing approximately $1.55 unfavorable EPS impact. Large one-time acquisition charges reduce near-term reported earnings, though the long-term strategic rationale depends on Alesta's pipeline value not yet apparent in this filing.

BioMarin bought Alesta and will take a $320 million accounting charge this year, reducing reported profits by about $1.55 per share. These are one-time costs from the deal, not ongoing operational problems.